Crinetics Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Caren Deardorf

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Caren Deardorf”): 73,454,076 for, 23,532,328 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 41,526,369 for, 6,242,834 withheld, 54 abstained.

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

Description as filed by funds: To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Stephanie S. Okey, M.S.

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Stephanie S. Okey, M.S.”): 72,225,313 for, 24,761,091 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 41,466,576 for, 6,302,626 withheld, 55 abstained.

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

Description as filed by funds: To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Weston Nichols, Ph.D.

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Weston Nichols, Ph.D.”): 90,208,564 for, 6,777,840 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 47,506,873 for, 262,366 withheld, 17 abstained.

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 91,657,992 for, 2,698,538 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three - Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Crinetics Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, 26 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 74 managers: 46,991,174 for, 771,503 against, 5,978 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 236 managers: 74,931,787 for, 1,893,079 against, 2,605,225 abstained, 1,643 not voted, 1,151,418 mixed. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of PricewaterhouseCoopers LLP ("PwC") as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Selection of Independent Registered Public Accounting Firm”): 101,675,974 for, 341,727 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 47,763,284 for, 1 against, 5,971 abstained.

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.